How frequent are invasive therapies required in patients receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study

Authors

  • KAZUKI KAWABE,

    Corresponding author
    1. Tokyo Teishin Hospital,
      Kazuki Kawabe md, Tokyo Teishin Hospital, 2/14/23 Fujimi Chiyoda-ku, Tokyo 102-8798, Japan. Email: kkawabe@tth-japanpost.jp
    Search for more papers by this author
  • YUKIO HOMMA,

    1. Department of Urology, Japanese Red Cross Medical Center,
    Search for more papers by this author
  • KIYOSHI KUBOTA,

    1. Department of Pharmacoepidemiology, Faculty of Medicine, The University of Tokyo, and
    Search for more papers by this author
  • TAKASHI SOZU,

    1. Department of Industrial Management and Engineering, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan
    Search for more papers by this author
  • THE TAMSULOSIN LONG-TERM STUDY GROUP

    Search for more papers by this author
    • The Tamsulosin Long-term Study Group: Baba Yoshikazu, Shuto General Hospital; Hayashida Shigeaki, Tokuyama Central Hospital; Hirao Hiroshi, Hirao Urological Clinic; Hironaka Hiroshi, Hironaka Urological Clinic; Homma Yukio, Japanese Red Cross Medical Center; Kamiryo Yoriaki, Saiseikai Shimonoseki General Hospital; Katsumi Tetsuo, Kanazawa Medical Center; Principal investigator: Kawabe Kazuki, Tokyo Teishin Hospital; Kawaguchi Kouhei, Noto General Hospital; Kawakita Mutsushi, Kobe City General Hospital; Kubota Kiyoshi, University of Tokyo; Masuda Aiichiro, Tokai University Oiso Hospital; Matsushita Kazuo, Tokai University Tokyo Hospital; Miki Tsuneharu, University Hospital, Kyoto Prefectural University of Medicine; Naito Katsusuke, Yamaguchi University Hospital; Saito Nobuharu, Otsuki Municipal Central Hospital; Shimabukuro Tomoyuki, Ube Industries Central Hospital; Sozu Takashi, Tokyo University of Science; Sugimoto Toshikado, Osaka City General Hospital; Terachi Toshiro, Tokai University Hospital; Terai Akito, Kurashiki Central Hospital; Terunuma Masahiro, Nagaoka Chuo General Hospital; Yamada Yutaka, Ichikawamisato Municipal Hospital; Yamaguchi Akito, Harasanshin Hospital; Yamauchi Masafumi, Nagato General Hospital.


Kazuki Kawabe md, Tokyo Teishin Hospital, 2/14/23 Fujimi Chiyoda-ku, Tokyo 102-8798, Japan. Email: kkawabe@tth-japanpost.jp

Abstract

Abstract  Three hundred Japanese patients with benign prostatic hyperplasia (BPH) who started an α1-adrenoceptor blocker, tamsulosin, between 1993 and 1996 were followed for 3.0 ± 3.3 years (mean ± SD) to determine whether an association existed between the disease severities measured prior to the tamsulosin treatment and the timing at which the invasive therapy was implemented. Patients with a lower quality of life (QOL) index or maximum urinary flow rate (Qmax) were transferred for invasive therapy earlier than those with less severe BPH. The International Prostate Symptom Score (I-PSS) was also associated, but apparently to a lesser extent, with the timing of the invasive therapy. Finally, the overall severity evaluated using all of the above three indices, I-PSS, QOL index, and Qmax, in accordance with the ‘Severity Criteria for BPH’ issued by the Japanese Urological Association, was found to be a good measure for predicting the prognosis of patients with BPH treated with tamsulosin.

Ancillary